240 related articles for article (PubMed ID: 32348882)
1. Acceptability of an orodispersible film compared to syrup in neonates and infants: A randomized controlled trial.
Klingmann V; Pohly CE; Meissner T; Mayatepek E; Möltner A; Flunkert K; Breitkreutz J; Bosse HM
Eur J Pharm Biopharm; 2020 Jun; 151():239-245. PubMed ID: 32348882
[TBL] [Abstract][Full Text] [Related]
2. Acceptability of small-sized oblong tablets in comparison to syrup and mini-tablets in infants and toddlers: A randomized controlled trial.
Münch J; Meissner T; Mayatepek E; Wargenau M; Breitkreutz J; Bosse HM; Klingmann V
Eur J Pharm Biopharm; 2021 Sep; 166():126-134. PubMed ID: 34153451
[TBL] [Abstract][Full Text] [Related]
3. Acceptability of Multiple Uncoated Minitablets in Infants and Toddlers: A Randomized Controlled Trial.
Klingmann V; Linderskamp H; Meissner T; Mayatepek E; Moeltner A; Breitkreutz J; Bosse HM
J Pediatr; 2018 Oct; 201():202-207.e1. PubMed ID: 29960767
[TBL] [Abstract][Full Text] [Related]
4. Acceptability of multiple coated mini-tablets in comparison to syrup in infants and toddlers: a randomised controlled study.
Klingmann V; Hinder M; Langenickel TH; Chen F; Khder Y; Breitkreutz J; Bosse HM
Arch Dis Child; 2023 Sep; 108(9):730-735. PubMed ID: 36963813
[TBL] [Abstract][Full Text] [Related]
5. Acceptability of orodispersible films for delivery of medicines to infants and preschool children.
Orlu M; Ranmal SR; Sheng Y; Tuleu C; Seddon P
Drug Deliv; 2017 Nov; 24(1):1243-1248. PubMed ID: 28856931
[TBL] [Abstract][Full Text] [Related]
6. Acceptability of Uncoated Mini-Tablets in Neonates--A Randomized Controlled Trial.
Klingmann V; Seitz A; Meissner T; Breitkreutz J; Moeltner A; Bosse HM
J Pediatr; 2015 Oct; 167(4):893-896.e2. PubMed ID: 26259675
[TBL] [Abstract][Full Text] [Related]
7. Prolonged release from orodispersible films by incorporation of diclofenac-loaded micropellets.
Speer I; Lenhart V; Preis M; Breitkreutz J
Int J Pharm; 2019 Jan; 554():149-160. PubMed ID: 30414477
[TBL] [Abstract][Full Text] [Related]
8. A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population.
Wargenau M; Reidemeister S; Klingmann I; Klingmann V
Ther Innov Regul Sci; 2022 Nov; 56(6):903-909. PubMed ID: 35471561
[TBL] [Abstract][Full Text] [Related]
9. Trends in the production methods of orodispersible films.
Musazzi UM; Khalid GM; Selmin F; Minghetti P; Cilurzo F
Int J Pharm; 2020 Feb; 576():118963. PubMed ID: 31857185
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children: Results from an Open-Label, Single-Dose, Cross-Over Study.
Münch J; Sessler I; Bosse HM; Wargenau M; Dreesen JD; Loforese G; Webb NJA; Sivasubramanian R; Reidemeister S; Lustenberger P; Klingmann V
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376177
[TBL] [Abstract][Full Text] [Related]
11. Application of miniaturized near-infrared spectroscopy for quality control of extemporaneous orodispersible films.
Foo WC; Widjaja E; Khong YM; Gokhale R; Chan SY
J Pharm Biomed Anal; 2018 Feb; 150():191-198. PubMed ID: 29247960
[TBL] [Abstract][Full Text] [Related]
12. Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics.
Thabet Y; Klingmann V; Breitkreutz J
J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S26-S35. PubMed ID: 30248193
[TBL] [Abstract][Full Text] [Related]
13. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects.
van Riet-Nales DA; Schobben AF; Vromans H; Egberts TC; Rademaker CM
Arch Dis Child; 2016 Jul; 101(7):662-9. PubMed ID: 26979250
[TBL] [Abstract][Full Text] [Related]
14. How to assess orodispersible film quality? A review of applied methods and their modifications.
Wasilewska K; Winnicka K
Acta Pharm; 2019 Jun; 69(2):155-176. PubMed ID: 31259725
[TBL] [Abstract][Full Text] [Related]
15. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
Freerks L; Sommerfeldt J; Löper PC; Klein S
Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
[TBL] [Abstract][Full Text] [Related]
16. Key acceptability attributes of orodispersible films.
Scarpa M; Paudel A; Kloprogge F; Hsiao WK; Bresciani M; Gaisford S; Orlu M
Eur J Pharm Biopharm; 2018 Apr; 125():131-140. PubMed ID: 29355687
[TBL] [Abstract][Full Text] [Related]
17. Orodispersible films - Recent developments and new applications in drug delivery and therapy.
Morath B; Sauer S; Zaradzki M; Wagner AH
Biochem Pharmacol; 2022 Jun; 200():115036. PubMed ID: 35427572
[TBL] [Abstract][Full Text] [Related]
18. Trends in the Characterization Methods of Orodispersible Films.
Khalid GM; Selmin F; Musazzi UM; Gennari CGM; Minghetti P; Cilurzo F
Curr Drug Deliv; 2021 Dec; 18(7):935-946. PubMed ID: 33305704
[TBL] [Abstract][Full Text] [Related]
19. A novel unit-dose approach for the pharmaceutical compounding of an orodispersible film.
Foo WC; Khong YM; Gokhale R; Chan SY
Int J Pharm; 2018 Mar; 539(1-2):165-174. PubMed ID: 29414124
[TBL] [Abstract][Full Text] [Related]
20. Pediatric drug development: formulation considerations.
Ali AA; Charoo NA; Abdallah DB
Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
